Patent Grant
8876746
This disclosure pertains to electrosurgical systems and methods for treating tissue, in particular, an electrosurgical method for treating chronic wound tissue whereby an active electrode in the presence of plasma is directed to perforate and/or debride the wound tissue, remove debris and pathogens from the wound bed, induce blood flow, and leverage the body's metabolic, vascular, molecular, and biochemical response to promote, stimulate, and stabilize the healing process.
Wound healing is the body's natural response for repairing and regenerating dermal and epidermal tissue. Wound healing is generally categorized into four stages: 1) clotting/hemostasis stage; 2) inflammatory stage; 3) tissue cell proliferation stage; and 4) tissue cell remodeling stage. The wound healing process is complex and fragile and may be susceptible to interruption or failure, especially in the instance of chronic wounds. A wound that does not heal in a predictable amount of time and in the orderly set of stages for typical wound healing may be categorized as chronic. For instance, wounds that do not heal within approximately one month from the point of inception are often categorized as chronic, and in some cases chronic wounds may never heal or may take years to do so. A number of factors may overwhelm the body's ability to effectively heal a wound, such as repeated trauma, continued pressure, an overriding illness, infection, or a restriction in blood supply to the wound area. More specifically, because the body's response to chronic wounds is often overwhelmed, the healing response goes awry, resulting in instability and disorganization in the healing process.
Chronic wounds may become caught in one or more of the four stages of wound healing, such as remaining in the inflammatory stage for too long, and thereby preventing the wound healing process to naturally progress. Similarly, a chronic wound may fail to adequately finish one stage of healing before moving on to the next, resulting in interference between the healing stages and potentially causing processes to repeat without an effective end. By way of further example, during the stage of epithelialization in typical wound healing, epithelial cells are formed at the edges of the wound or in proximity to a border or rim surrounding the wound bed and proliferate over the wound bed to cover it, continuing until the cells from various sides meet in the middle. Affected by various growth factors, the epithelial cells proliferate over the wound bed, engulfing and eliminating debris and pathogens found in the wound bed such as dead or necrotic tissue and bacterial matter that would otherwise obstruct their path and delay or prevent wound healing and closure. However, the epithelialization process in chronic wounds may be short-circuited or ineffective as the epithelial cells, needing living tissue to migrate across the wound bed, do not rapidly proliferate over the wound bed, or in some instances do not adequately respond at all during this particular stage of wound healing. As such, a need arises with chronic wounds to sterilize the wound site, as well as to establish communication between healthy tissue and wound tissue to promote epithelialization, fibroblast and epithelial migration, and neovascularization, and to bridge the gaps (i.e., including but not limited to structural and vascular gaps) between vital tissue surrounding the wound bed and tissue on the periphery of and within the wound bed itself.
Certain chronic wounds can be classified as ulcers of some type (i.e., diabetic ulcers, venous ulcers, and pressure ulcers). An ulcer is a break in a skin or a mucus membrane evident by a loss of surface tissue, tissue disintegration, necrosis of epithelial tissue, nerve damage and pus. Venous ulcers typically occur in the legs and are thought to be attributable to either chronic venous insufficiency or a combination of arterial and venous insufficiency, resulting in improper blood flow and/or a restriction in blood flow that causes tissue damage leading to the wound. Pressure ulcers typically occur in people with limited mobility or paralysis, where the condition of the person inhibits movement of body parts that are commonly subjected to pressure. Pressure ulcers, commonly referred to as “bed sores,” are caused by ischemia that occurs when the pressure on the tissue is greater than the blood pressure in the capillaries at the wound site, thus restricting blood flow into the area.
For patients with long-standing diabetes and with poor glycemic control, a common condition is a diabetic foot ulcer, symptoms of which include slow healing surface lesions with peripheral neuropathy (which inhibits the perception of pain), arterial insufficiency, damage to small blood vessels, poor vascularization, ischemia of surrounding tissue, deformities, cellulitis tissue formation, high rates of infection and inflammation. Cellulitis tissue includes callous and fibrotic tissue. Thus, due to the often concomitant loss of sensation in the wound area, diabetic patients may not initially notice small, non-lesioned wounds to legs and feet, and may therefore fail to prevent infection or repeated injury. If left untreated a diabetic foot ulcer can become infected and gangrenous which can result in disfiguring scars, foot deformity, and/or amputation.
As illustrated in
Typically, ulcer treatment is dependant upon its location, size, depth, and appearance to determine whether it is neuropathic, ischemic, or neuro-ischemic. Depending on the diagnosis, antibiotics may be administered and if further treatment is necessary, the symptomatic area is treated more aggressively (e.g., by surgical debridement using a scalpel, scissors, or other instrument to cut necrotic and/or infected tissue from the wound, mechanical debridement using the removal of dressing adhered to the wound tissue, or chemical debridement using certain enzymes and other compounds to dissolve wound tissue) to remove unhealthy tissue and induce blood flow and to expose healthy underlying structure. Often, extensive post-debridement treatment such as dressings, foams, hydrocolloids, genetically engineered platelet-derived growth factor becaplermin and bio-engineered skins and the like may also be utilized.
Additionally, several other types of wounds may progress to a chronic, non-healing condition. For example, surgical wounds at the site of incision may progress inappropriately to a chronic wound or may progress to pathological scarring such as a keloid scar. Trauma wounds may similarly progress to chronic wound status due to infection or involvement of other factors within the wound bed that inhibit proper healing. Burn treatment and related skin grafting procedures may also be compromised due to improper wound healing response and the presence of chronic wound formation characteristics. In various types of burns, ulcers, and amputation wounds, skin grafting may be required. In certain instances, patients with ischemia or poor vascularity may experience difficulty in the graft “taking” resulting in the need for multiple costly skin grafting procedures. Finally, in patients where the risk of infection is high due to a weakened immune system (i.e., tissue impacted by radiation, patients undergoing cancer treatments, patients affected by immune compromised diseases such as HIV/AIDS), inflammation of a wound may be prolonged thereby interfering with the wound healing process and leading to wounds more susceptible to develop into chronic wounds, particularly where the wound site is unable to be sufficiently sterilized.
Various methods exist for treatment of chronic wounds, including antibiotic and antibacterial use, surgical or mechanical debridement, irrigation, topical chemical treatment, warming, oxygenation, and moist wound healing, which remain subject to several shortcomings in their efficacy. Accordingly, there remains a need for new and improved methods for use in the treatment of chronic wounds that address certain of the forgoing difficulties.
According to one embodiment, the method is an electrosurgical procedure for treating wound tissue, in particular a chronic wound tissue, comprising: positioning an active electrode in close proximity to the wound, the active electrode disposed on a distal end of an electrosurgical probe or shaft; applying a high-frequency voltage potential difference across the active electrode and a return electrode sufficient to develop a high electric field intensity associated with a vapor layer proximate the active electrode wherein the high electric field intensity stimulates the wound tissue and an expression of at least one healing mediator in the wound tissue. In certain embodiments, an electrically conductive fluid is provided proximate the active electrode, such that the fluid is vaporized and ionized to thereby form a plasma. Modification of the wound tissue in accordance with the present method may include perforating tissue on and in the vicinity of the wound, debriding tissue to induce blood flow, debriding necrotic tissue both on the periphery of the wound bed and within the wound bed itself, removing biofilm and bacteria from the wound bed, and applying plasma and associated RF electric energy to stimulate or induce a metabolic, biochemical, and/or physiological change in the wound tissue and surrounding tissue, and thereby leverage the body's natural healing response. In other embodiments, the active electrode is inserted into the wound tissue to perforate and remove necrotic or unhealthy tissue, restore blood flow and promote healing.
Various electrode configurations may be utilized according to the desired manner of treatment of the wound tissue. In certain electrode configurations, an electrically conductive fluid may be provided proximate the active electrode to generate plasma. Depending on the apparatus used, the conductive fluid may be provided by a fluid delivery lumen that discharges the fluid in the vicinity of the target tissue. The fluid delivery lumen may be integrated with the electrosurgical instrument or may be provided separately therefrom. Alternatively, a conductive gel or other medium may be applied to the target tissue prior to treatment. Similarly, in alternate embodiments, an aspiration lumen may be provided to remove fluid and body tissue from the vicinity of the target tissue.
In using high electric field intensities associated with a vapor layer to modify the wound tissue, the present method utilizes the RF electric energy to stimulate healing and wound closure, remove necrotic or unhealthy tissue as well as biofilm and bacteria, and improve blood flow. Ischemia underlying a chronic wound may be treated by utilizing plasma to volumetrically dissociate and remove wound tissue in order to debride portions of the wound tissue and/or to create perforations or artificial channels, thereby triggering a healing response concomitant with revascularization or neovascularization in portions of the wound tissue. The use of plasma to stimulate healing and modify wound tissue through removal of necrotic tissue also leverages the body's cytokine role in coordinating inflammatory response and repairing tissue as described in “Percutaneous Plasma Discectomy Stimulates Repair In Injured Intervertebral Discs,” Conor W. O'Neill, et al, Department of Orthopedic Surgery, Department of Radiology, University of California, San Francisco, Calif. (2004), incorporated herein by reference.
As noted in the O'Neil reference, electrosurgical plasma alters the expression of inflammatory response in tissue, leading to a decrease in interlukin-1 (IL-1) and an increase in interlukin-8 (IL-8). While both IL-1 and IL-8 have hyperalgesic properties, IL-1 is likely to be the more important pathophysiologic factor in pain disorders than IL-8. Also, as described in the O'Neil reference, cytokines play an important role in coordinating inflammatory and repair response to tissue injury. For example, IL-1 is a catabolic mediator that induces proteases and inhibits extra-cellular matrix synthesis. On the other hand, IL-8 is anabolic as it promotes a number of tissue repair functions including formation of provisional extra-cellular matrices, angiogenesis, fibroblast proliferation and differentiation, stem cell mobilization, and maturation and remodeling of extra-cellular matrices.
With respect to chronic wounds, ischemia may cause tissue to become inflamed and tissue cells to release inflammatory cytokines, and may also contribute to factors that attract IL-1 interleukins that may damage cells and prevent cell proliferation. Thus, by altering the expression of cytokines such that there is a decrease in IL-1 and an increase in IL-8, it is suggested that plasma has a role in stimulating a healing response mediated by IL-8 to mediate tissue regeneration, resulting in overall tissue healing, an a decrease in inflammation and pain. Increased IL-8 levels attributable to the presently described electrosurgical procedures may also play a role in enhanced wound sterilization as a result of the higher rate of neutrophil attraction to the inflamed chronic wound site. Acute infection at a wound site may lead to chronic wound development, and may further result in gangrene, loss of the infected limb, and possibly death. Neutrophils produce reactive oxygen species (ROS) that combat infection and kill bacteria colonizing a wound bed, such that increased attraction of neutrophils through the resultant higher IL-8 levels described above may have a sterilizing role through addressing wound infection and bacteria levels, as well as limiting the possibility of extended inflammation in the wound tissue that delays healing and further damages tissue associated with chronic wounds. Furthermore, the presence of increased levels of IL-8 may assist in counteracting the fibroblast gene expression characteristic in chronic wounds that is attributed to failure of the fibroblast to produce an adequate metabolic response to epithelialize the wound.
Similarly, enhancement of several key biochemical markers is a significant aspect of proper wound healing response. Growth factors are imperative in successful wound healing, and inadequate growth factor levels can be a significant contributor in chronic wound formation. For example, in chronic wounds the formation and release of growth factors necessary for wound healing may be under-expressed, prevented or constrained, such that the growth factors are unable to effectively perform their roles in the healing response. By utilizing the effects of electrosurgical ablation according to the presently described methods to stimulate one or more growth factors such as vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), and epidermal growth factor (EGF), the proliferation, migration to the wound bed, and production of new extracellular matrix components by fibroblasts may be preferably encouraged. Furthermore, treatment of wound tissue with the electrosurgical ablative procedures described herein may also beneficially increase wound bed sterility as well as promote formation of collagen and granulation tissue as part of the reepithelialization phase of wound healing.
The temperature effect of electrosurgical ablation according to the presently described methods may also have an influence on an improved wound healing response. During the ablative process, a steep temperature gradient away from the electrosurgical probe may preferably be created, suggesting that a majority of the tissue cells in the vicinity of the electrically conductive fluid are preferably exposed to non-fatal cell stress. However, in correlation to the limited temperature effect is an observation of elevated levels of heat shock proteins such as heat shock protein-70 (Hsp70). As described in “The Short Term Effects of Electrosurgical Ablation on Proinflammatory Mediator Production by Intervertebral Disc Cells in Tissue Culture,” Kee-Won Rhyu, et al, Department of Orthopedic Surgery, Department of Radiology, University of California, San Francisco, Calif. (2007), incorporated herein by reference, the level of Hsp70 of treated cells was transiently increased after ablation and may have been induced by the non-fatal cell stress effected by ablation. Changes in Hsp70 levels indicate that ablation may alter the cell stress environment, and that ablation may be tied to elevating Hsp70 activity responsible for cellular recovery, survival, and maintenance of normal cellular function.
The methods described for promoting a wound healing response can result in a variety of biochemical, metabolic, physiological, or anatomical changes that invoke a stabilized healing response to chronic wound tissue. The desired response may be attributed to numerous factors, including gene expression, nerve stimulation, stimulation of greater blood flow, collagen growth, alteration of cellular function, treatment site sterilization, or other biochemical or metabolic events that promote healing, repair, and regeneration of injured tissue. In some embodiments, these induced changes may include increased anabolic tissue cellular response including angiogenesis, fibroblast proliferation, and stabilized remodeling of extra-cellular matrices. The changes may further include increased nerve stimulation, cell metabolism, increased collagen synthesis in fibroblasts, transformation of fibroblasts to myofibroblasts, increased capillary formation with enhanced microcirculation, and/or enhanced clearance of noxious substances associated with the inflammatory response. In other embodiments, the wound healing response may include an increased blood flow to, and vascularization or revascularization of, the treated wound region, thereby promoting healing and regeneration of injured tissue. In yet other embodiments, the wound healing response may include stimulating the growth of new collagen in the treatment area.
Since the method can be applied at any stage of the condition, the method can therefore be used to treat chronic wound tissue both before and after a lesion forms. Hence, the early stages of the condition before extensive tissue damage have occurred may be preventatively treated, as well as treating affected areas at a later stage when there is extensive tissue damage and cellulitis.
Embodiments of the present methods and system are described and illustrated in the following detailed specification.
Certain terms are used throughout the following description and claims to refer to particular system components. As one skilled in the art will appreciate, companies that design and manufacture electrosurgical systems may refer to a component by different names. This document does not intend to distinguish between components that differ in name but not function.
In the following discussion and in the claims, the terms “including” and “comprising” are used in an open-ended fashion, and thus should be interpreted to mean “including, but not limited to . . . .” Also, the term “couple” or “couples” is intended to mean either an indirect or direct connection. Thus, if a first device couples to a second device, that connection may be through a direct connection or through an indirect electrical connection via other devices and connections.
Reference to a singular item includes the possibility that there are plural of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “an,” “said” and “the” include plural references unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement serves as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation. Lastly, it is to be appreciated that unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
“Active electrode” shall mean an electrode of an electrosurgical wand which produces an electrically-induced tissue-altering effect when brought into contact with, or close proximity to, a tissue targeted for treatment, and/or an electrode having a voltage induced thereon by a voltage generator.
“Return electrode” shall mean an electrode of an electrosurgical wand which serves to provide a current flow path for electrons with respect to an active electrode, and/or an electrode of an electrosurgical wand which does not itself produce an electrically-induced tissue-altering effect on tissue targeted for treatment.
“Chronic wound tissue” shall mean wound tissue that does not heal in an orderly set of stages and in a predictable amount of time, including but not limited to wound tissue attributable to diabetic ulcers, venous ulcers, pressure ulcers, surgical wounds, trauma wounds, burns, amputation wounds, radiated tissue, tissue affected by chemotherapy treatment, and/or infected tissue compromised by a weakened immune system.
“Healing mediator” shall mean mechanisms associated with wound healing that may be expressed by the body during the wound healing process, including but not limited to cytokines, interleukin (IL)-8, vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), epidermal growth factor (EGF), and heat shock protein-70 (Hsp70).
Where a range of values is provided, it is understood that every intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein.
All existing subject matter mentioned herein (e.g., publications, patents, patent applications and hardware) is incorporated by reference herein in its entirety except insofar as the subject matter may conflict with that of the present invention (in which case what is present herein shall prevail). The referenced items are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such material by virtue of prior invention.
In the drawings and description that follows, like parts are marked throughout the specification and drawings with the same reference numerals, respectively. The drawing figures are not necessarily to scale. Certain features of the invention may be shown exaggerated in scale or in somewhat schematic form and some details of conventional elements may not be shown in the interest of clarity and conciseness. The present invention is susceptible to embodiments of different forms. Specific embodiments are described in detail and are shown in the drawings, with the understanding that the present disclosure is to be considered an exemplification of the principles of the invention, and is not intended to limit the invention to that illustrated and described herein. It is to be fully recognized that the different teachings of the embodiments discussed below may be employed separately or in any suitable combination to produce desired results.
Electrosurgical apparatus and systems adaptable for use with the present method are illustrated and described in commonly owned U.S. Pat. Nos. 6,296,638, 6,589,237, 6,602,248, and 6,805,130, the disclosures of which are herein incorporated by reference. In one exemplary embodiment illustrated in
As used herein, an active electrode is an electrode that is adapted to generate a higher charge density relative to a return electrode, and hence operable to generate a plasma in the vicinity of the active electrode when a high-frequency voltage potential is applied across the electrodes, as described herein. Typically, a higher charge density is obtained by making the active electrode surface area smaller relative to the surface area of the return electrode.
Power supply (26) comprises selection means (28) to change the applied voltage level. The power supply (26) can also include a foot pedal (32) positioned close to the user for energizing the electrodes (16A, 16B). The foot pedal (32) may also include a second pedal (not shown) for remotely adjusting the voltage level applied to electrodes (16A, 16B). Also included in the system is an electrically conductive fluid supply (36) with tubing (34) for supplying the probe (10) and the electrodes with electrically conductive fluid. Details of a power supply that may be used with the electrosurgical probe of the present invention is described in commonly owned U.S. Pat. No. 5,697,909 which is hereby incorporated by reference herein.
As illustrated in
As will be appreciated, the above-described systems and apparatus can applied equally well to a wide range of electrosurgical procedures including open procedures, intravascular procedures, urological, laparoscopic, arthroscopic, thoracoscopic or other cardiac procedures, as well as dermatological, orthopedic, gynecological, otorhinolaryngological, spinal, and neurologic procedures, oncology and the like. However, for the present purposes the system and methods described herein are directed to treat various forms of breaks in skin tissue and chronic surface tissue wounds, including but not limited to skin ulcers, mucus membrane ulcers, foot ulcers, cellulitic tissue, venous ulcers, pressure ulcers, diabetic foot ulcers, surgical wounds, trauma wounds, burns, amputation wounds, wound exacerbated by immune compromised disease, and wounds associated with radiation and chemotherapy treatments.
The assignee of the present invention developed Coblation® technology. Coblation® technology involves the application of a high frequency voltage difference between one or more active electrode(s) and one or more return electrode(s) to develop high electric field intensities in the vicinity of the target tissue. The high electric field intensities may be generated by applying a high frequency voltage that is sufficient to vaporize an electrically conductive fluid and form a vapor layer over at least a portion of the active electrode(s) in the region between the tip of the active electrode(s) and the target tissue. The electrically conductive fluid may be a liquid or gas, such as isotonic saline, Ringers' lactate solution, blood, extracellular or intracellular fluid, delivered to, or already present at, the target site, or a viscous fluid, such as a gel, applied to the target site.
When the conductive fluid is heated enough such that atoms vaporize off the surface faster than they recondense, a gas is formed. When the gas is sufficiently heated such that the atoms collide with each other causing a release of electrons in the process, an ionized gas or plasma is formed (the so-called “fourth state of matter”). Generally speaking, plasmas may be formed by heating a gas and ionizing the gas by driving an electric current through it, or by shining radio waves into the gas. These methods of plasma formation give energy to free electrons in the plasma directly, and then electron-atom collisions liberate more electrons, and the process cascades until the desired degree of ionization is achieved. A more complete description of plasma can be found in Plasma Physics, by R. J. Goldston and P. H. Rutherford of the Plasma Physics Laboratory of Princeton University (1995), the complete disclosure of which is incorporated herein by reference.
As the density of the plasma or vapor layer becomes sufficiently low (i.e., less than approximately 1020 atoms/cm3 for aqueous solutions), the electron mean free path increases to enable subsequently injected electrons to cause impact ionization within the vapor layer. Once the ionic particles in the plasma layer have sufficient energy, they accelerate towards the target tissue. This ionization, under these conditions, induces the discharge of plasma comprised of energetic electrons and photons from the vapor layer and to the surface of the target tissue. Energy evolved by the energetic electrons (e.g., 3.5 eV to 5 eV) can subsequently bombard a molecule and break its bonds, dissociating a molecule into free radicals, which then combine into final gaseous or liquid species. Among the byproducts of this type of ablation are hydroxyl radicals, which have been shown to influence IL-8 expression. See Rhyu, “Short Term Effects of Electrosurgical Ablation,” at 455. Often, the electrons carry the electrical current or absorb the radio waves and, therefore, are hotter than the ions. Thus, the electrons, which are carried away from the tissue towards the return electrode, carry most of the plasma's heat with them, allowing the ions to break apart the tissue molecules in a substantially non-thermal manner.
By means of this molecular dissociation (rather than thermal evaporation or carbonization), the target tissue structure is preferably volumetrically removed through molecular disintegration of larger organic molecules into smaller molecules and/or atoms, such as hydrogen, oxygen, oxides of carbon, hydrocarbons and nitrogen compounds. This molecular disintegration completely removes the tissue structure, as opposed to dehydrating the tissue material by the removal of liquid within the cells of the tissue and extracellular fluids, as is typically the case with electrosurgical desiccation and vaporization. Further, because the vapor layer or vaporized region has relatively high electrical impedance, it minimizes current flow into the electrically conductive fluid. A more detailed description of these phenomena, termed Coblation®, can be found in commonly assigned U.S. Pat. Nos. 5,683,366 and 5,697,882, the complete disclosures of which are incorporated herein by reference.
In certain embodiments of the present method, the applied high frequency voltage can be used to modify tissue in several ways, e.g., current can be passed directly into the target site by direct contact with the electrodes such to heat the target site; or current can be passed indirectly into the target site through an electrically conductive fluid located between the electrode and the target site also to heat the target site; or current can be passed into an electrically conductive fluid disposed between the electrodes to generate plasma for treating the target site. In accordance with the present method, the system of
In various embodiments of the present method, the electrically conductive fluid possesses an electrical conductivity value above a minimum threshold level, in order to provide a suitable conductive path between the return electrode and the active electrode(s). The electrical conductivity of the fluid (in units of milliSiemens per centimeter or mS/cm) is usually be greater than about 0.2 mS/cm, typically greater than about 2 mS/cm and more typically greater than about 10 mS/cm. In an exemplary embodiment, the electrically conductive fluid is isotonic saline, which has a conductivity of about 17 mS/cm.
Also in various embodiments of the preset method, it may be necessary to remove, e.g., aspirate, any excess electrically conductive fluid and/or ablation by-products from the surgical site. In addition, it may be desirable to aspirate small pieces of tissue that are not completely disintegrated by the high frequency energy, or other fluids at the target site, such as blood, mucus, and other body fluids. Accordingly, in various embodiments the present system includes one or more aspiration lumen(s) in the shaft, or on another instrument, coupled to a suitable vacuum source for aspirating fluids from the target site. In various embodiments, the instrument also includes one or more aspiration active electrode(s) coupled to the aspiration lumen for inhibiting clogging during aspiration of tissue fragments from the surgical site. A more complete description of these embodiments can be found in commonly owned U.S. Pat. No. 6,190,381, the complete disclosure of which is incorporated herein by reference for all purposes.
In certain embodiments of the present method, a single electrode or an electrode array may be disposed over a distal end of the shaft of the electrosurgical instrument to generate the plasma that is subsequently applied to the target tissue. In most configurations, the circumscribed area of the electrode or electrode array will generally depend on the desired diameter of the perforations and amount of tissue debriding to be performed. In one embodiment, the area of the electrode array is in the range of from about 0.10 mm2 to 40 mm2, preferably from about 0.5 mm2 to 10 mm2, and more preferably from about 0.5 mm2 to 5.0 mm2.
In addition, the shape of the electrode at the distal end of the instrument shaft will also depend on the size of the chronic wound tissue surface area to be treated. For example, the electrode may take the form of a pointed tip, a solid round wire, or a wire having other solid cross-sectional shapes such as squares, rectangles, hexagons, triangles, star-shaped, or the like, to provide a plurality of edges around the distal perimeter of the electrodes. Alternatively, the electrode may be in the form of a hollow metal tube or loop having a cross-sectional shape that is round, square, hexagonal, rectangular or the like. The envelope or effective diameter of the individual electrode(s) ranges from about 0.05 mm to 6.5 mm, preferably from about 0.1 mm to 2 mm. Furthermore, the electrode may in the form of a screen disposed at the distal end of the shaft and having an opening therethrough for aspiration of excess fluid and ablation byproducts.
Examples of an electrosurgical apparatus that can be used to modify tissue in accordance with the present method are illustrated in
Similarly, with reference to
With reference to
Referring now to
Referring now to
Referring now to
In a typical procedure involving treatment of a chronic wound according to the present method, it may be necessary to use one or more shapes of electrode configuration described above, either alone or in combination. For example, in a first step, an electrode of the type illustrated in either
Typically, during debridement procedures that utilize an electrode configuration of the type illustrated in
In certain embodiments, apparatus (100) preferably debrides the wound tissue to the extent that a bleeding wound bed is prepared suitable for wound closure or skin graft application. As discussed above, it is vital to epithelialization that the wound bed is clear of debris and pathogens that may block epithelial cell proliferation from the edges of the wound bed. Additionally, it is critical that the epithelial cells have access and exposure to living or viable tissue in order to efficiently migrate across the wound bed. Therefore, by utilizing apparatus (100) to debride tissue adjacent to and within the wound bed to the extent a bleeding wound bed is prepared, a suitable environment for epithelialization may be provided.
In certain embodiments, apparatus (100) may be used to remove necrotic tissue from within and adjacent to the wound bed and to remove non-viable tissue forming a border or rim around the wound bed. Additionally, apparatus (100) may be utilized to treat the wound bed in order to remove bacterial matter and other pathogens to promote the sterilization of the treated site. In this manner of tissue removal and wound treatment, barriers to epithelial cell migration are eliminated, and improved communication between healthy tissue and wound tissue is established. Furthermore, gaps in the vascular structure between the wound bed and surrounding healthy tissue may be bridged by removing the border or rim of necrotic or non-viable tissue surrounding the wound bed.
Active electrodes (110) are particularly effective for debriding tissue because they provide a greater current concentration to the tissue at the target site. The greater current concentration may be used to aggressively create a plasma within the electrically conductive fluid, and hence a more efficient debridement of tissue at the target site. In use, active electrodes (110) are typically employed to ablate tissue using the Coblation® mechanisms as described above. Voltage is applied between active electrodes (110) and return electrode (116) to volumetrically loosen fragments from the target site through molecular dissociation. Once the tissue fragments are loosened from the target site, the tissue fragments can be ablated in situ with the plasma (i.e., break down the tissue by processes including molecular dissociation or disintegration), removed via an aspiration lumen, or removed via irrigation or other suitable method. In certain embodiments, active electrodes (110) provide a relatively uniform smooth debriding effect across the wound tissue. Additionally, active electrodes (110) generally provide a larger surface area exposed to electrically conductive fluid as compared to the smaller active electrodes described above and referenced in
As referenced above, in certain other embodiments the apparatus (110) may be provided with aspiration lumen (142) and electrically conductive fluid delivery lumen (150) (
Further, it is preferable that the conductive fluid delivery lumen is positioned such that the fluid delivery lumen port is located in a configuration that allows the conductive fluid to be delivered partially around the active electrodes thereby immersing the active electrodes with conductive fluid during the debridement procedure. Additionally, configurations where the aspiration port is spaced proximally from the active electrode may be desirable. As a result of the above-described fluid delivery and aspiration port positioning, conductive fluid such as saline is delivered to the target site during use of the instrument and allowed to remain in contact with the active electrodes and target tissue for a longer period of time. By delivering the conductive fluid in proximity to the active electrodes and spacing the aspiration port proximate from the active electrodes, the dwell time of the conductive fluid near the active electrodes is increased in order to create more aggressive plasma. Improved and more aggressive plasma creation at the treatment site may result in an increase in the rate of ablation of tissue fragments, thereby primarily aspirating blood and gas bubbles from the target area and allowing for less clogging of the aspiration lumen.
As referenced above, in certain embodiments an electrode configuration as shown in
Applicants believe that the presently-described methods of treatment for chronic wound tissue utilizing the above-referenced electrosurgical devices evokes a more organized and coordinated healing response than is typically associated with chronic wounds. Specifically, the application of high frequency voltage and resulting plasma to chronic wound tissue, in conjunction with the ensuing debridement and/or perforation of the wound tissue, stimulates and modulates an expression of healing mediators such as growth factors, heat shock proteins, and cytokines, and promotes a stabilized wound healing response attributable to a variety of biochemical, metabolic, and/or physiological changes. As referenced above, with respect to chronic wounds the wound healing process may often go awry such that the wound is never allowed to completely or properly heal. Chronic wounds may be subject to a healing response characterized by stages repeating in an open loop where one stage cannot be completed and subsequent stages of the process cannot begin, are interfered with, or are compromised. By stimulating and modifying the wound tissue in the method described above (i.e., through the application of electrical energy and plasma), the wound healing process is effectively put back on track and allowed to progress to its natural end.
For example, in certain embodiments the treatment method described herein may invoke a healing response that includes gene expression in the form of altered cytokine levels conducive to halting tissue degeneration and to promoting the proliferation of fibroblasts. Applicants believe that the resultant gene expression stimulates the treated tissue to form novel structures that invoke a proper wound healing process and advances the process through the incomplete stage and toward the completion of the process. By way of additional example, Applicants believe that the application of plasma to chronic wound tissue results in increased blood flow, vascularization, or revascularization in the treated area, which promotes healing and regeneration of healthy tissue in the wound region.
As discussed above, in using any of the contemplated electrode configurations it is desirable to remove at least a portion of the necrotic chronic wound tissue via debridement or perforation to promote wound healing and closure. More specifically, whether the best treatment procedure is determined to be that of larger scale debridement or perforation, or some combination thereof, it is preferable to remove unhealthy tissue both on the periphery, border or rim, of the wound bed, as well as from within the wound bed itself. Concomitant with tissue removal via electrosurgical ablation according to the methods described herein is a collateral stimulative effect from the RF electric fields generated by the electrosurgical process. In certain embodiments, the treatment of wound tissue via the described electrosurgical ablative debridement results in the stimulation of surrounding layers of tissue—both in substantially horizontal and vertical directions from the wound bed—such that a macro-stimulation of tissue from the RF energy is generated. Therefore, the stimulative RF effect contemplated by the present methods is both across the wound bed surface such that the adjacent wound border or rim tissue is affected, but also, down through deeper tissue layers found below the wound bed such that underlying tissue structures may be influenced.
The above-described stimulation preferably provides for sufficient but not excessive production of healing mediators associated with the wound bed tissue debridement. According to the desired methods of treatment, there is an initial healing mediator response from each tissue stimulus associated with the electrosurgical RF treatment and tissue removal, which is preferably followed with subsequent repeated and periodic treatments to overlap treatments responses and restart the cascade of healing mediators.
In some instances, the stimulation may extend to nerves proximate to the treatment area, resulting in a return of sensation to the area where the wound tissue has been treated by way of debridement and/or perforation. Certain embodiments of the present method may include treating target tissue by the application of plasma and thereby modifying the wound tissue, resulting in increased nerve stimulation, increased capillary formation with enhanced microcirculation, and vascularization of the treated tissue. This may be especially beneficial in treatment methods for wounds with no open lesions.
In certain embodiments, wounds with no open or apparent lesions may be treated by perforating the target tissue through the application of high frequency voltage and the creation of plasma at the tip of an active electrode, resulting in nerve stimulation and revascularization. In treating pre-open wounds (e.g., calluses) by the described manner of electrosurgical perforation, ulcerated wound tissue is modified prior to the formation of lesions and is stimulated to induce sensation to return to the treated area. As a result, the patient may then preferably develop an improved awareness of excessive damaging contact and wear on the area and take preventative steps to correct the issues affecting the pre-lesion wound tissue prior to the formation of an open wound. This manner of preventative treatment may be particularly helpful to patients with diabetic foot ulcers who have lost sensation in an area with some cellulitis, where the desensitized are may be adversely affected by footwear and repeated rubbing or wear resulting from walking.
The area of the tissue treatment surface can vary widely, and the tissue treatment surface can assume a variety of geometries, with particular areas and geometries being selected for specific applications. The active electrode surface(s) can have area(s) in the range from about 0.25 mm2 to 75 mm2, usually being from about 0.5 mm2 to 40 mm2. The geometries can be planar, concave, convex, hemispherical, conical, linear “in-line” array, or virtually any other regular or irregular shape.
Most commonly, the active electrode(s) or active electrode array(s) will be formed at the distal tip of the electrosurgical instrument shaft, frequently being planar, disk-shaped, pointed or hemispherical surfaces for use in reshaping procedures, or being linear arrays for use in cutting. Alternatively or additionally, the active electrode(s) may be formed on lateral surfaces of the electrosurgical instrument shaft (e.g., in the manner of a spatula).
The voltage difference applied between the return electrode(s) and the return electrode is high or radio frequency, typically between about 5 kHz and 20 MHz, usually being between about 30 kHz and 2.5 MHz, preferably being between about 50 kHz and 500 kHz, more preferably less than 350 kHz, and most preferably between about 100 kHz and 200 kHz. The RMS (root mean square) voltage applied will usually be in the range from about 5 volts to 1000 volts, preferably being in the range from about 10 volts to 500 volts depending on the active electrode size, the operating frequency and the operation mode of the particular procedure or desired effect on the tissue (e.g., contraction, coagulation, cutting or ablation).
Typically, the peak-to-peak voltage for ablation or cutting of tissue will be in the range of from about 10 volts to 2000 volts, usually in the range of 200 volts to 1800 volts, and more typically in the range of about 300 volts to 1500 volts, often in the range of about 500 volts to 900 volts peak to peak (again, depending on the electrode size, the operating frequency and the operation mode). Lower peak-to-peak voltages will be used for tissue coagulation or collagen contraction and will typically be in the range from 50 to 1500, preferably from about 100 to 1000, and more preferably from about 120 to 600 volts peak-to-peak.
The power source may be current limited or otherwise controlled so that undesired heating of the target tissue or surrounding (non-target) tissue does not occur. In a preferred embodiment, current limiting inductors are placed in series with each independent active electrode, where the inductance of the inductor is in the range of 10 μH to 50,000 μH, depending on the electrical properties of the target tissue, the desired tissue heating rate and the operating frequency. Alternatively, capacitor-inductor (LC) circuit structures may be employed, as described previously in U.S. Pat. No. 5,697,909, the complete disclosure of which is incorporated herein by reference.
The current flow path between the active electrodes and the return electrode(s) may be generated by submerging the tissue site in an electrically conductive fluid (e.g., a viscous fluid, such as an electrically conductive gel), or by directing an electrically conductive fluid through a fluid outlet along a fluid path to saturate the target site (i.e., a liquid, such as isotonic saline, or a gas, such as argon). The conductive gel may also be delivered to the target site to achieve a slower more controlled delivery rate of conductive fluid. In addition, the viscous nature of the gel may allow the surgeon to more easily contain the gel around the target site (e.g., as compared with containment of a liquid, such as isotonic saline). A more complete description of an exemplary method of directing electrically conductive fluid between active and return electrodes is described in U.S. Pat. No. 5,697,281, the contents of which are incorporated by reference herein in their entirety.
With reference to
Referring now to
Referring now to
Referring now to
Referring now to
Referring now to
Referring now to
In certain embodiments, a conductive fluid such as isotonic saline, a conductive gel, Ringer's solution, or body fluid such as blood and body plasma, is present and is in contact with the active electrode. As noted above, the conductive fluid in the presence of a sufficiently high-frequency voltage will generate plasma as used in the present method. Preferably, the conductive fluid forms a conductive bridge between the active electrode and the return electrode. In these embodiments, the active and return electrodes are disposed on the distal end of an electrosurgical shaft as described above. Therefore, since current does not pass into the tissue, plasma generated in the conductive fluid is used to modify the tissue as described above.
In certain other embodiments, an electrically conductive fluid layer is provided in between the active electrode and the tissue, in the vicinity of the tissue. In these embodiments, in addition to plasma generated in the fluid, current from the applied high frequency voltage is applied into the tissue. Therefore, both current and plasma are used to modify the tissue. In alternative embodiments the applied high frequency voltage is adjusted to provide sufficient current for coagulating and sealing the tissue and stop bleeding.
In various embodiments of the method, a suitably configured active electrode is used to treat the chronic wound tissue, for example, by debriding, perforating, inducing blood-flow to tissue, coagulating tissue and/or volumetrically removing tissue in the vicinity of the wound. Thus, for example, an active electrode as schematically illustrated in
During procedures according to the present methods, the active electrode(s) are preferably translated axially and radially over the tissue in the proximity of the chronic wound tissue to volumetrically remove and modify the tissue. For larger and more complicated chronic wounds, an electrode with a wider tip and/or larger surface area as illustrated in
While preferred embodiments of this disclosure have been shown and described, modifications thereof can be made by one skilled in the art without departing from the scope or teaching herein. The embodiments described herein are exemplary only and are not limiting. Because many varying and different embodiments may be made within the scope of the present inventive concept, including equivalent structures, materials, or methods hereafter though of, and because many modifications may be made in the embodiments herein detailed in accordance with the descriptive requirements of the law, it is to be understood that the details herein are to be interpreted as illustrative and not in a limiting sense.
This application is a continuation-in-part of prior application Ser. No. 11/327,089, filed Jan. 6, 2006, and entitled “Electrosurgical Method and System for Treating Foot Ulcer,” hereby incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2050904 | Trice | Apr 1936 | A |
| 2056377 | Wappler | Oct 1939 | A |
| 2611365 | Rubens | Sep 1952 | A |
| 3434476 | Shaw et al. | Mar 1969 | A |
| 3633425 | Sanford | Jan 1972 | A |
| 3707149 | Hao et al. | Dec 1972 | A |
| 3718617 | Royal | Feb 1973 | A |
| 3815604 | O'Malley et al. | Jun 1974 | A |
| 3828780 | Morrison, Jr. et al. | Aug 1974 | A |
| 3901242 | Storz | Aug 1975 | A |
| 3920021 | Hiltebrandt | Nov 1975 | A |
| 3939839 | Curtiss | Feb 1976 | A |
| 3963030 | Newton | Jun 1976 | A |
| 3964487 | Judson | Jun 1976 | A |
| 3970088 | Morrison | Jul 1976 | A |
| 4033351 | Hetzel | Jul 1977 | A |
| 4040426 | Morrison, Jr. | Aug 1977 | A |
| 4043342 | Morrison, Jr. | Aug 1977 | A |
| 4074718 | Morrison, Jr. | Feb 1978 | A |
| 4092986 | Schneiderman | Jun 1978 | A |
| D249549 | Pike | Sep 1978 | S |
| 4114623 | Meinke et al. | Sep 1978 | A |
| 4116198 | Roos | Sep 1978 | A |
| 4181131 | Ogiu | Jan 1980 | A |
| 4184492 | Meinke et al. | Jan 1980 | A |
| 4202337 | Hren et al. | May 1980 | A |
| 4228800 | Degler, Jr. et al. | Oct 1980 | A |
| 4232676 | Herczog | Nov 1980 | A |
| 4240441 | Khalil | Dec 1980 | A |
| 4248231 | Herczog et al. | Feb 1981 | A |
| 4301801 | Schneiderman | Nov 1981 | A |
| 4326529 | Doss et al. | Apr 1982 | A |
| 4346715 | Gammell | Aug 1982 | A |
| 4363324 | Kusserow | Dec 1982 | A |
| 4378801 | Oosten | Apr 1983 | A |
| 4381007 | Doss | Apr 1983 | A |
| 4418692 | Guay | Dec 1983 | A |
| 4474179 | Koch | Oct 1984 | A |
| 4476862 | Pao | Oct 1984 | A |
| 4509532 | DeVries | Apr 1985 | A |
| 4520818 | Mickiewicz | Jun 1985 | A |
| 4532924 | Auth et al. | Aug 1985 | A |
| 4548207 | Reimels | Oct 1985 | A |
| 4567890 | Ohta et al. | Feb 1986 | A |
| 4572206 | Geddes et al. | Feb 1986 | A |
| 4580557 | Hertzmann | Apr 1986 | A |
| 4587975 | Salo et al. | May 1986 | A |
| 4590934 | Malis et al. | May 1986 | A |
| 4593691 | Lindstrom et al. | Jun 1986 | A |
| 4658817 | Hardy | Apr 1987 | A |
| 4660571 | Hess et al. | Apr 1987 | A |
| 4674499 | Pao | Jun 1987 | A |
| 4682596 | Bales et al. | Jul 1987 | A |
| 4706667 | Roos | Nov 1987 | A |
| 4709698 | Johnston et al. | Dec 1987 | A |
| 4727874 | Bowers et al. | Mar 1988 | A |
| 4750902 | Wuchinich et al. | Jun 1988 | A |
| 4765331 | Petruzzi et al. | Aug 1988 | A |
| 4785823 | Eggers et al. | Nov 1988 | A |
| 4805616 | Pao | Feb 1989 | A |
| 4823791 | D'Amelio et al. | Apr 1989 | A |
| 4832048 | Cohen | May 1989 | A |
| 4846179 | O'Connor | Jul 1989 | A |
| 4860752 | Turner | Aug 1989 | A |
| 4898169 | Norman et al. | Feb 1990 | A |
| 4907589 | Cosman | Mar 1990 | A |
| 4920978 | Colvin | May 1990 | A |
| 4931047 | Broadwin et al. | Jun 1990 | A |
| 4936281 | Stasz | Jun 1990 | A |
| 4936301 | Rexroth et al. | Jun 1990 | A |
| 4943290 | Rexroth et al. | Jul 1990 | A |
| 4955377 | Lennox et al. | Sep 1990 | A |
| 4966597 | Cosman | Oct 1990 | A |
| 4967765 | Turner et al. | Nov 1990 | A |
| 4976711 | Parins et al. | Dec 1990 | A |
| 4979948 | Geddes et al. | Dec 1990 | A |
| 4998933 | Eggers et al. | Mar 1991 | A |
| 5007908 | Rydell | Apr 1991 | A |
| 5009656 | Reimels | Apr 1991 | A |
| 5035696 | Rydell | Jul 1991 | A |
| 5047026 | Rydell | Sep 1991 | A |
| 5047027 | Rydell | Sep 1991 | A |
| 5057105 | Malone et al. | Oct 1991 | A |
| 5057106 | Kasevich et al. | Oct 1991 | A |
| 5078717 | Parins et al. | Jan 1992 | A |
| 5080660 | Buelna | Jan 1992 | A |
| 5083565 | Parins et al. | Jan 1992 | A |
| 5084044 | Quint | Jan 1992 | A |
| 5085659 | Rydell | Feb 1992 | A |
| 5088997 | Delahuerga et al. | Feb 1992 | A |
| 5092339 | Geddes et al. | Mar 1992 | A |
| 5098431 | Rydell | Mar 1992 | A |
| 5099840 | Goble | Mar 1992 | A |
| 5102410 | Dressel | Apr 1992 | A |
| 5108391 | Flachenecker et al. | Apr 1992 | A |
| RE33925 | Bales et al. | May 1992 | E |
| 5112330 | Nishigaki et al. | May 1992 | A |
| 5122138 | Manwaring | Jun 1992 | A |
| 5125928 | Parins et al. | Jun 1992 | A |
| 5156151 | Imran | Oct 1992 | A |
| 5167659 | Ohtomo et al. | Dec 1992 | A |
| 5171311 | Rydell et al. | Dec 1992 | A |
| 5174304 | Latina et al. | Dec 1992 | A |
| 5178620 | Eggers et al. | Jan 1993 | A |
| 5183338 | Wickersheim et al. | Feb 1993 | A |
| 5190517 | Zieve et al. | Mar 1993 | A |
| 5192280 | Parins | Mar 1993 | A |
| 5195959 | Smith | Mar 1993 | A |
| 5197466 | Marchosky et al. | Mar 1993 | A |
| 5197963 | Parins | Mar 1993 | A |
| 5207675 | Canady | May 1993 | A |
| 5217457 | Delahuerga et al. | Jun 1993 | A |
| 5217459 | Kamerling | Jun 1993 | A |
| 5249585 | Turner et al. | Oct 1993 | A |
| 5255980 | Thomas et al. | Oct 1993 | A |
| 5261410 | Alfano et al. | Nov 1993 | A |
| 5267994 | Gentelia et al. | Dec 1993 | A |
| 5267997 | Farin et al. | Dec 1993 | A |
| 5273524 | Fox et al. | Dec 1993 | A |
| 5277201 | Stern | Jan 1994 | A |
| 5281216 | Klicek | Jan 1994 | A |
| 5281218 | Imran | Jan 1994 | A |
| 5282799 | Rydell | Feb 1994 | A |
| 5290282 | Casscells | Mar 1994 | A |
| 5300069 | Hunsberger et al. | Apr 1994 | A |
| 5306238 | Fleenor | Apr 1994 | A |
| 5312400 | Bales et al. | May 1994 | A |
| 5314406 | Arias et al. | May 1994 | A |
| 5318563 | Malis et al. | Jun 1994 | A |
| 5324254 | Phillips | Jun 1994 | A |
| 5330470 | Hagen | Jul 1994 | A |
| 5334140 | Phillips | Aug 1994 | A |
| 5334183 | Wuchinich | Aug 1994 | A |
| 5334193 | Nardella | Aug 1994 | A |
| 5336220 | Ryan et al. | Aug 1994 | A |
| 5336443 | Odashima | Aug 1994 | A |
| 5342357 | Nardella | Aug 1994 | A |
| 5348554 | Imran et al. | Sep 1994 | A |
| 5366443 | Eggers et al. | Nov 1994 | A |
| 5370675 | Edwards et al. | Dec 1994 | A |
| 5374261 | Yoon | Dec 1994 | A |
| 5375588 | Yoon | Dec 1994 | A |
| 5380277 | Phillips | Jan 1995 | A |
| 5380316 | Aita | Jan 1995 | A |
| 5383874 | Jackson et al. | Jan 1995 | A |
| 5383876 | Nardella | Jan 1995 | A |
| 5383917 | Desai et al. | Jan 1995 | A |
| 5389096 | Aita | Feb 1995 | A |
| 5395312 | Desai | Mar 1995 | A |
| 5400267 | Denen et al. | Mar 1995 | A |
| 5401272 | Perkins | Mar 1995 | A |
| 5403311 | Abele et al. | Apr 1995 | A |
| 5417687 | Nardella et al. | May 1995 | A |
| 5419767 | Eggers et al. | May 1995 | A |
| 5423810 | Goble et al. | Jun 1995 | A |
| 5423882 | Jackman et al. | Jun 1995 | A |
| 5436566 | Thompson et al. | Jul 1995 | A |
| 5437662 | Nardella | Aug 1995 | A |
| 5438302 | Goble | Aug 1995 | A |
| 5441499 | Fritzsch | Aug 1995 | A |
| 5449356 | Walbrink et al. | Sep 1995 | A |
| 5451224 | Goble et al. | Sep 1995 | A |
| 5454809 | Janssen | Oct 1995 | A |
| 5458596 | Lax et al. | Oct 1995 | A |
| 5458597 | Edwards et al. | Oct 1995 | A |
| 5472443 | Cordis et al. | Dec 1995 | A |
| 5486161 | Lax et al. | Jan 1996 | A |
| 5496312 | Klicek | Mar 1996 | A |
| 5496314 | Eggers | Mar 1996 | A |
| 5496317 | Goble et al. | Mar 1996 | A |
| 5505730 | Edwards et al. | Apr 1996 | A |
| 5507743 | Edwards et al. | Apr 1996 | A |
| 5514130 | Baker | May 1996 | A |
| 5540683 | Ichikawa et al. | Jul 1996 | A |
| 5542915 | Edwards et al. | Aug 1996 | A |
| 5549598 | O'Donnell, Jr. | Aug 1996 | A |
| 5554152 | Aita | Sep 1996 | A |
| 5556397 | Long et al. | Sep 1996 | A |
| 5562703 | Desai | Oct 1996 | A |
| 5569242 | Lax et al. | Oct 1996 | A |
| 5571100 | Goble et al. | Nov 1996 | A |
| 5573533 | Strul | Nov 1996 | A |
| 5584872 | LaFontaine et al. | Dec 1996 | A |
| 5588960 | Edwards et al. | Dec 1996 | A |
| 5599350 | Schulze et al. | Feb 1997 | A |
| 5609151 | Mulier et al. | Mar 1997 | A |
| 5633578 | Eggers et al. | May 1997 | A |
| 5634921 | Hood et al. | Jun 1997 | A |
| 5643304 | Schechter et al. | Jul 1997 | A |
| 5647869 | Goble et al. | Jul 1997 | A |
| 5658278 | Imran et al. | Aug 1997 | A |
| 5660567 | Nierlich et al. | Aug 1997 | A |
| 5662680 | Desai | Sep 1997 | A |
| 5676693 | LaFontaine et al. | Oct 1997 | A |
| 5681282 | Eggers et al. | Oct 1997 | A |
| 5683366 | Eggers et al. | Nov 1997 | A |
| 5697281 | Eggers et al. | Dec 1997 | A |
| 5697536 | Eggers et al. | Dec 1997 | A |
| 5697882 | Eggers et al. | Dec 1997 | A |
| 5697909 | Eggers et al. | Dec 1997 | A |
| 5697927 | Imran et al. | Dec 1997 | A |
| 5700262 | Acosta et al. | Dec 1997 | A |
| 5715817 | Stevens-Wright et al. | Feb 1998 | A |
| 5722975 | Edwards et al. | Mar 1998 | A |
| 5725524 | Mulier et al. | Mar 1998 | A |
| 5749869 | Lindenmeier et al. | May 1998 | A |
| 5749871 | Hood et al. | May 1998 | A |
| 5749914 | Janssen | May 1998 | A |
| 5755753 | Knowlton | May 1998 | A |
| 5766153 | Eggers et al. | Jun 1998 | A |
| 5769847 | Panescu et al. | Jun 1998 | A |
| 5785705 | Baker | Jul 1998 | A |
| 5786578 | Christy et al. | Jul 1998 | A |
| 5800429 | Edwards | Sep 1998 | A |
| 5807395 | Mulier et al. | Sep 1998 | A |
| 5810764 | Eggers et al. | Sep 1998 | A |
| 5810802 | Panescu et al. | Sep 1998 | A |
| 5810809 | Rydell | Sep 1998 | A |
| 5836875 | Webster, Jr. | Nov 1998 | A |
| 5836897 | Sakurai et al. | Nov 1998 | A |
| 5843019 | Eggers et al. | Dec 1998 | A |
| 5860951 | Eggers | Jan 1999 | A |
| 5860974 | Abele | Jan 1999 | A |
| 5860975 | Goble et al. | Jan 1999 | A |
| 5871469 | Eggers et al. | Feb 1999 | A |
| 5873855 | Eggers et al. | Feb 1999 | A |
| 5873877 | McGaffigan et al. | Feb 1999 | A |
| 5885277 | Korth | Mar 1999 | A |
| 5888198 | Eggers et al. | Mar 1999 | A |
| 5891095 | Eggers et al. | Apr 1999 | A |
| 5891134 | Goble et al. | Apr 1999 | A |
| 5897553 | Mulier | Apr 1999 | A |
| 5902272 | Eggers et al. | May 1999 | A |
| 5944715 | Goble et al. | Aug 1999 | A |
| 5954716 | Sharkey et al. | Sep 1999 | A |
| 5964786 | Ochs et al. | Oct 1999 | A |
| 6004319 | Goble et al. | Dec 1999 | A |
| 6013076 | Goble et al. | Jan 2000 | A |
| 6015406 | Goble et al. | Jan 2000 | A |
| 6024733 | Eggers et al. | Feb 2000 | A |
| 6027501 | Goble et al. | Feb 2000 | A |
| 6039734 | Goble et al. | Mar 2000 | A |
| 6047700 | Eggers et al. | Apr 2000 | A |
| 6056746 | Goble et al. | May 2000 | A |
| 6063079 | Hovda et al. | May 2000 | A |
| 6066134 | Eggers et al. | May 2000 | A |
| 6066489 | Fields et al. | May 2000 | A |
| 6068628 | Fanton et al. | May 2000 | A |
| 6074386 | Goble et al. | Jun 2000 | A |
| 6086585 | Hovda et al. | Jul 2000 | A |
| 6090106 | Goble et al. | Jul 2000 | A |
| 6090107 | Borgmeier et al. | Jul 2000 | A |
| 6093186 | Goble et al. | Jul 2000 | A |
| 6102046 | Weinstein et al. | Aug 2000 | A |
| 6105581 | Eggers et al. | Aug 2000 | A |
| 6109268 | Thapliyal et al. | Aug 2000 | A |
| 6117109 | Eggers et al. | Sep 2000 | A |
| 6126682 | Sharkey et al. | Oct 2000 | A |
| 6135999 | Fanton et al. | Oct 2000 | A |
| 6142992 | Cheng et al. | Nov 2000 | A |
| 6149620 | Baker et al. | Nov 2000 | A |
| 6156334 | Meyer-Ingold et al. | Dec 2000 | A |
| 6159194 | Eggers et al. | Dec 2000 | A |
| 6159208 | Hovda et al. | Dec 2000 | A |
| 6162217 | Kannenberg et al. | Dec 2000 | A |
| 6168593 | Sharkey et al. | Jan 2001 | B1 |
| 6174309 | Wrublewski et al. | Jan 2001 | B1 |
| 6179824 | Eggers et al. | Jan 2001 | B1 |
| 6179836 | Eggers et al. | Jan 2001 | B1 |
| 6183469 | Thapliyal et al. | Feb 2001 | B1 |
| 6190381 | Olsen et al. | Feb 2001 | B1 |
| 6197021 | Panescu et al. | Mar 2001 | B1 |
| 6203542 | Ellsberry et al. | Mar 2001 | B1 |
| 6210402 | Olsen et al. | Apr 2001 | B1 |
| 6210405 | Goble et al. | Apr 2001 | B1 |
| 6224592 | Eggers et al. | May 2001 | B1 |
| 6228078 | Eggers | May 2001 | B1 |
| 6228081 | Goble | May 2001 | B1 |
| 6235020 | Cheng et al. | May 2001 | B1 |
| 6237604 | Burnside et al. | May 2001 | B1 |
| 6238391 | Olsen et al. | May 2001 | B1 |
| 6238393 | Mulier et al. | May 2001 | B1 |
| 6241723 | Heim et al. | Jun 2001 | B1 |
| 6249706 | Sobota et al. | Jun 2001 | B1 |
| 6254600 | Willink et al. | Jul 2001 | B1 |
| 6258087 | Edwards et al. | Jul 2001 | B1 |
| 6261286 | Goble et al. | Jul 2001 | B1 |
| 6261311 | Sharkey et al. | Jul 2001 | B1 |
| 6264652 | Eggers et al. | Jul 2001 | B1 |
| 6270460 | McCartan et al. | Aug 2001 | B1 |
| 6277112 | Underwood et al. | Aug 2001 | B1 |
| 6280441 | Ryan | Aug 2001 | B1 |
| 6283961 | Underwood et al. | Sep 2001 | B1 |
| 6293942 | Goble et al. | Sep 2001 | B1 |
| 6296636 | Cheng et al. | Oct 2001 | B1 |
| 6296638 | Davison et al. | Oct 2001 | B1 |
| 6306134 | Goble et al. | Oct 2001 | B1 |
| 6308089 | von der Ruhr et al. | Oct 2001 | B1 |
| 6309387 | Eggers et al. | Oct 2001 | B1 |
| 6312408 | Eggers et al. | Nov 2001 | B1 |
| 6319007 | Livaditis | Nov 2001 | B1 |
| 6322549 | Eggers et al. | Nov 2001 | B1 |
| 6345104 | Rhoads et al. | Feb 2002 | B1 |
| 6346104 | Daly et al. | Feb 2002 | B2 |
| 6346107 | Cucin | Feb 2002 | B1 |
| 6355032 | Hovda et al. | Mar 2002 | B1 |
| 6363937 | Hovda et al. | Apr 2002 | B1 |
| 6364877 | Goble et al. | Apr 2002 | B1 |
| 6379351 | Thapliyal et al. | Apr 2002 | B1 |
| 6391025 | Weinstein et al. | May 2002 | B1 |
| 6409722 | Hoey et al. | Jun 2002 | B1 |
| 6416507 | Eggers et al. | Jul 2002 | B1 |
| 6416508 | Eggers et al. | Jul 2002 | B1 |
| 6416509 | Goble et al. | Jul 2002 | B1 |
| 6425912 | Knowlton | Jul 2002 | B1 |
| 6432103 | Ellsberry et al. | Aug 2002 | B1 |
| 6440129 | Simpson | Aug 2002 | B1 |
| 6468274 | Alleyne et al. | Oct 2002 | B1 |
| 6468275 | Wampler et al. | Oct 2002 | B1 |
| 6482201 | Olsen et al. | Nov 2002 | B1 |
| 6500173 | Underwood et al. | Dec 2002 | B2 |
| 6514248 | Eggers et al. | Feb 2003 | B1 |
| 6514250 | Jahns et al. | Feb 2003 | B1 |
| 6517498 | Burbank et al. | Feb 2003 | B1 |
| 6530922 | Cosman | Mar 2003 | B2 |
| 6558382 | Jahns et al. | May 2003 | B2 |
| 6565560 | Goble et al. | May 2003 | B1 |
| 6578579 | Burnside | Jun 2003 | B2 |
| 6589237 | Woloszko et al. | Jul 2003 | B2 |
| 6602248 | Sharps et al. | Aug 2003 | B1 |
| 6620156 | Garito et al. | Sep 2003 | B1 |
| 6632193 | Davison et al. | Oct 2003 | B1 |
| 6632220 | Eggers et al. | Oct 2003 | B1 |
| 6635034 | Cosmescu | Oct 2003 | B1 |
| 6640128 | Vilsmeier et al. | Oct 2003 | B2 |
| 6656177 | Truckai et al. | Dec 2003 | B2 |
| 6663554 | Babaev | Dec 2003 | B2 |
| 6663627 | Francischelli et al. | Dec 2003 | B2 |
| 6730080 | Harano et al. | May 2004 | B2 |
| 6749604 | Eggers et al. | Jun 2004 | B1 |
| 6749608 | Garito et al. | Jun 2004 | B2 |
| D493530 | Reschke | Jul 2004 | S |
| 6770071 | Woloszko et al. | Aug 2004 | B2 |
| 6780178 | Palanker et al. | Aug 2004 | B2 |
| 6780180 | Goble et al. | Aug 2004 | B1 |
| 6780184 | Tanrisever | Aug 2004 | B2 |
| 6802842 | Ellman et al. | Oct 2004 | B2 |
| 6805130 | Tasto et al. | Oct 2004 | B2 |
| 6830558 | Flaherty et al. | Dec 2004 | B2 |
| 6837887 | Woloszko et al. | Jan 2005 | B2 |
| 6837888 | Ciarrocca et al. | Jan 2005 | B2 |
| 6855143 | Davison et al. | Feb 2005 | B2 |
| 6864686 | Novak et al. | Mar 2005 | B2 |
| 6866671 | Tierney et al. | Mar 2005 | B2 |
| 6872183 | Sampson et al. | Mar 2005 | B2 |
| 6878149 | Gatto | Apr 2005 | B2 |
| 6890307 | Kokate et al. | May 2005 | B2 |
| 6892086 | Russell | May 2005 | B2 |
| 6911027 | Edwards et al. | Jun 2005 | B1 |
| 6915806 | Pacek et al. | Jul 2005 | B2 |
| 6920883 | Bessette et al. | Jul 2005 | B2 |
| 6921398 | Carmel et al. | Jul 2005 | B2 |
| 6929640 | Underwood et al. | Aug 2005 | B1 |
| 6949096 | Davison et al. | Sep 2005 | B2 |
| 6960204 | Eggers et al. | Nov 2005 | B2 |
| 6974453 | Woloszko et al. | Dec 2005 | B2 |
| 6979328 | Baerveldt et al. | Dec 2005 | B2 |
| 6979601 | Marr et al. | Dec 2005 | B2 |
| 6984231 | Goble et al. | Jan 2006 | B2 |
| 6986700 | Agarwal | Jan 2006 | B2 |
| 6986770 | Hood | Jan 2006 | B2 |
| 6991631 | Woloszko et al. | Jan 2006 | B2 |
| 7001382 | Gallo | Feb 2006 | B2 |
| 7004941 | Tvinnereim et al. | Feb 2006 | B2 |
| 7010353 | Gan et al. | Mar 2006 | B2 |
| 7041102 | Truckai et al. | May 2006 | B2 |
| 7070596 | Woloszko et al. | Jul 2006 | B1 |
| 7090672 | Underwood et al. | Aug 2006 | B2 |
| 7094215 | Davison et al. | Aug 2006 | B2 |
| 7094231 | Ellman et al. | Aug 2006 | B1 |
| 7104986 | Hovda et al. | Sep 2006 | B2 |
| 7115139 | McClurken et al. | Oct 2006 | B2 |
| 7131969 | Hovda et al. | Nov 2006 | B1 |
| 7169143 | Eggers et al. | Jan 2007 | B2 |
| 7179255 | Lettice et al. | Feb 2007 | B2 |
| 7186234 | Dahla et al. | Mar 2007 | B2 |
| 7192428 | Eggers et al. | Mar 2007 | B2 |
| 7201750 | Eggers et al. | Apr 2007 | B1 |
| 7217268 | Eggers et al. | May 2007 | B2 |
| 7223265 | Keppel | May 2007 | B2 |
| 7241293 | Davison | Jul 2007 | B2 |
| 7247155 | Hoey et al. | Jul 2007 | B2 |
| 7270658 | Woloszko et al. | Sep 2007 | B2 |
| 7270659 | Ricart et al. | Sep 2007 | B2 |
| 7270661 | Dahla et al. | Sep 2007 | B2 |
| 7271363 | Lee et al. | Sep 2007 | B2 |
| 7276063 | Davison et al. | Oct 2007 | B2 |
| 7278994 | Goble | Oct 2007 | B2 |
| 7282048 | Goble et al. | Oct 2007 | B2 |
| 7297143 | Woloszko et al. | Nov 2007 | B2 |
| 7297145 | Ormsby et al. | Nov 2007 | B2 |
| 7318823 | Sharps et al. | Jan 2008 | B2 |
| 7331956 | Hovda et al. | Feb 2008 | B2 |
| 7335199 | Goble et al. | Feb 2008 | B2 |
| RE40156 | Sharps et al. | Mar 2008 | E |
| 7344532 | Goble et al. | Mar 2008 | B2 |
| 7357798 | Sharps et al. | Apr 2008 | B2 |
| 7387625 | Hovda et al. | Jun 2008 | B2 |
| 7419488 | Ciarrocca et al. | Sep 2008 | B2 |
| 7429260 | Underwood et al. | Sep 2008 | B2 |
| 7429262 | Woloszko et al. | Sep 2008 | B2 |
| 7435247 | Woloszko et al. | Oct 2008 | B2 |
| 7442191 | Hovda et al. | Oct 2008 | B2 |
| 7445618 | Eggers et al. | Nov 2008 | B2 |
| 7449021 | Underwood et al. | Nov 2008 | B2 |
| 7462178 | Woloszko et al. | Dec 2008 | B2 |
| 7468059 | Eggers et al. | Dec 2008 | B2 |
| 7491200 | Underwood et al. | Feb 2009 | B2 |
| 7678069 | Baker et al. | Mar 2010 | B1 |
| 7691101 | Davison et al. | Apr 2010 | B2 |
| 7699830 | Martin | Apr 2010 | B2 |
| 7722601 | Wham et al. | May 2010 | B2 |
| 7785322 | Penny et al. | Aug 2010 | B2 |
| 7824398 | Woloszko et al. | Nov 2010 | B2 |
| 7862560 | Marion | Jan 2011 | B2 |
| 7985072 | Belikov et al. | Jul 2011 | B2 |
| D658760 | Cox et al. | May 2012 | S |
| 8192424 | Woloszko | Jun 2012 | B2 |
| 8303583 | Hosier et al. | Nov 2012 | B2 |
| 8372067 | Woloszko et al. | Feb 2013 | B2 |
| 20020029036 | Goble et al. | Mar 2002 | A1 |
| 20020042612 | Hood et al. | Apr 2002 | A1 |
| 20020151882 | Marko et al. | Oct 2002 | A1 |
| 20020183739 | Long | Dec 2002 | A1 |
| 20030013986 | Saadat | Jan 2003 | A1 |
| 20030014045 | Russell | Jan 2003 | A1 |
| 20030014047 | Woloszko et al. | Jan 2003 | A1 |
| 20030088245 | Woloszko et al. | May 2003 | A1 |
| 20030130655 | Woloszko et al. | Jul 2003 | A1 |
| 20030158545 | Hovda et al. | Aug 2003 | A1 |
| 20030171743 | Tasto et al. | Sep 2003 | A1 |
| 20030181903 | Hood et al. | Sep 2003 | A1 |
| 20030208196 | Stone | Nov 2003 | A1 |
| 20030212396 | Eggers et al. | Nov 2003 | A1 |
| 20030216725 | Woloszko et al. | Nov 2003 | A1 |
| 20030216732 | Truckai et al. | Nov 2003 | A1 |
| 20030232048 | Yang et al. | Dec 2003 | A1 |
| 20040030330 | Brassell et al. | Feb 2004 | A1 |
| 20040116922 | Hovda et al. | Jun 2004 | A1 |
| 20040127893 | Hovda | Jul 2004 | A1 |
| 20040186418 | Karashima | Sep 2004 | A1 |
| 20040186470 | Goble et al. | Sep 2004 | A1 |
| 20040230190 | Dahla et al. | Nov 2004 | A1 |
| 20050004634 | Ricart et al. | Jan 2005 | A1 |
| 20050033278 | McClurken et al. | Feb 2005 | A1 |
| 20050119650 | Sanders et al. | Jun 2005 | A1 |
| 20050251134 | Woloszko et al. | Nov 2005 | A1 |
| 20050261754 | Woloszko et al. | Nov 2005 | A1 |
| 20050273091 | Booth et al. | Dec 2005 | A1 |
| 20050288665 | Woloszko et al. | Dec 2005 | A1 |
| 20060036237 | Davison et al. | Feb 2006 | A1 |
| 20060095031 | Ormsby | May 2006 | A1 |
| 20060161148 | Behnke | Jul 2006 | A1 |
| 20060178670 | Woloszko et al. | Aug 2006 | A1 |
| 20060189971 | Tasto et al. | Aug 2006 | A1 |
| 20060253117 | Hovda et al. | Nov 2006 | A1 |
| 20060259025 | Dahla | Nov 2006 | A1 |
| 20070010808 | Dahla | Jan 2007 | A1 |
| 20070106288 | Woloszko et al. | May 2007 | A1 |
| 20070149966 | Dahla et al. | Jun 2007 | A1 |
| 20070161981 | Sanders et al. | Jul 2007 | A1 |
| 20070179497 | Eggers et al. | Aug 2007 | A1 |
| 20070208334 | Woloszko et al. | Sep 2007 | A1 |
| 20070208335 | Woloszko et al. | Sep 2007 | A1 |
| 20070213700 | Davison et al. | Sep 2007 | A1 |
| 20070282323 | Woloszko et al. | Dec 2007 | A1 |
| 20080004621 | Dahla et al. | Jan 2008 | A1 |
| 20080077128 | Woloszko et al. | Mar 2008 | A1 |
| 20080138761 | Pond | Jun 2008 | A1 |
| 20080140069 | Filloux et al. | Jun 2008 | A1 |
| 20080154255 | Panos et al. | Jun 2008 | A1 |
| 20080167645 | Woloszko | Jul 2008 | A1 |
| 20080234671 | Marion | Sep 2008 | A1 |
| 20080300590 | Horne et al. | Dec 2008 | A1 |
| 20090209956 | Marion | Aug 2009 | A1 |
| 20090216222 | Davison et al. | Aug 2009 | A1 |
| 20090216223 | Davison et al. | Aug 2009 | A1 |
| 20090216224 | Davison et al. | Aug 2009 | A1 |
| 20090216226 | Davison et al. | Aug 2009 | A1 |
| 20090216227 | Davison et al. | Aug 2009 | A1 |
| 20090222001 | Greeley | Sep 2009 | A1 |
| 20090222004 | Davison et al. | Sep 2009 | A1 |
| 20100087812 | Davison et al. | Apr 2010 | A1 |
| 20100152726 | Cadouri et al. | Jun 2010 | A1 |
| 20100228246 | Marion | Sep 2010 | A1 |
| 20100292689 | Davison et al. | Nov 2010 | A1 |
| 20100318083 | Davison et al. | Dec 2010 | A1 |
| 20100324549 | Marion | Dec 2010 | A1 |
| 20120083782 | Stalder et al. | Apr 2012 | A1 |
| 20120109123 | Woloszko et al. | May 2012 | A1 |
| 20120196251 | Taft et al. | Aug 2012 | A1 |
| 20120197344 | Taft et al. | Aug 2012 | A1 |
| 20120215221 | Woloszko | Aug 2012 | A1 |
| 20120296328 | Marion | Nov 2012 | A1 |
| Number | Date | Country |
|---|---|---|
| 3119735 | Jan 1983 | DE |
| 3930451 | Mar 1991 | DE |
| 423757 | Mar 1996 | EP |
| 0703461 | Mar 1996 | EP |
| 0740926 | Nov 1996 | EP |
| 0 754 437 | Jan 1997 | EP |
| 0 694 290 | Nov 2000 | EP |
| 1334699 | Aug 2003 | EP |
| 1428480 | Jun 2004 | EP |
| 1707147 | Oct 2006 | EP |
| 2313949 | Jan 1977 | FR |
| 467502 | Jun 1937 | GB |
| 2160102 | Dec 1985 | GB |
| 2299216 | Sep 1996 | GB |
| 2 308 979 | Jul 1997 | GB |
| 2 308 980 | Jul 1997 | GB |
| 2 308 981 | Jul 1997 | GB |
| 2 327 350 | Jan 1999 | GB |
| 2 327 351 | Jan 1999 | GB |
| 2 327 352 | Jan 1999 | GB |
| 2333455 | Jul 1999 | GB |
| 2406793 | Apr 2005 | GB |
| 57-57802 | Apr 1982 | JP |
| 57-117843 | Jul 1982 | JP |
| 9003152 | Apr 1990 | WO |
| 9007303 | Jul 1990 | WO |
| 9221278 | Dec 1992 | WO |
| 9313816 | Jul 1993 | WO |
| 9320747 | Oct 1993 | WO |
| 9404220 | Mar 1994 | WO |
| 9408654 | Apr 1994 | WO |
| 9410921 | May 1994 | WO |
| 9426228 | Nov 1994 | WO |
| 9534259 | Dec 1995 | WO |
| 9600040 | Jan 1996 | WO |
| 9600042 | Jan 1996 | WO |
| 9639086 | Dec 1996 | WO |
| 9700646 | Jan 1997 | WO |
| 9700647 | Jan 1997 | WO |
| 9718768 | May 1997 | WO |
| 9724073 | Jul 1997 | WO |
| 9724074 | Jul 1997 | WO |
| 9724993 | Jul 1997 | WO |
| 9724994 | Jul 1997 | WO |
| 9743971 | Nov 1997 | WO |
| 9748345 | Dec 1997 | WO |
| 9748346 | Dec 1997 | WO |
| 9807468 | Feb 1998 | WO |
| 9826724 | Jun 1998 | WO |
| 9827879 | Jul 1998 | WO |
| 9827880 | Jul 1998 | WO |
| 9920213 | Apr 1999 | WO |
| 9951155 | Oct 1999 | WO |
| 9951158 | Oct 1999 | WO |
| 9956648 | Nov 1999 | WO |
| 0000098 | Jan 2000 | WO |
| 0009053 | Feb 2000 | WO |
| 0062685 | Oct 2000 | WO |
| 0124720 | Apr 2001 | WO |
| 0187154 | May 2001 | WO |
| 0195819 | Dec 2001 | WO |
| 02102255 | Feb 2002 | WO |
| 0236028 | May 2002 | WO |
| 03024305 | Mar 2003 | WO |
| 03092477 | Nov 2003 | WO |
| 2004026150 | Apr 2004 | WO |
| 2004071278 | Aug 2004 | WO |
| 2005125287 | Dec 2005 | WO |
| 2006116252 | Nov 2006 | WO |
| 2007006000 | Jan 2007 | WO |
| 2007056729 | May 2007 | WO |
| 2010052717 | May 2010 | WO |
| 2012050636 | Apr 2012 | WO |
| 2012050637 | Apr 2012 | WO |
| Entry |
|---|
| O'Neill, Conor W. et al., “Percutaneous Plasma Decompression Alters Cytokine Expression in Injured Porcine Intervertebral Discs,” The Spine Journal 4, pp. 88-98, 2004. |
| Robinson, Andrew J., “Electrical Stimulation to Augment Healing of Chronic Wounds”, Clinical Electrophysiology-Electrotherapy and Electrophysiologic Testing, Third Edition, pp. 275-299, 2008. |
| European Examination Report 2 for EP 04708664 5pgs, May 3, 2010. |
| European Search Report for EP 04708664.0 5pgs, Apr. 6, 2009. |
| European Search Report for EP 09152850, 2 pgs, Dec. 29, 2009. |
| UK Search Report for GB0900604.0 4 pgs, May 15, 2009. |
| European Examination Report for EP 02773432 4 pgs, Sep. 22, 2009. |
| European Examination Report for EP 04708664 7pgs, Sep. 7, 2009. |
| European Examination Report for EP 02749601.7 4pgs, Dec. 2, 2009. |
| Extended European Search Report for EP09152846, 8pgs, Jan. 5, 2010. |
| Extended European Search Report for EP07797827, 8pgs, Mar. 1, 2010. |
| Barry et al., “The Effect of Radiofrequency-generated Thermal Energy on the Mechanical and Histologic Characteristics of the Arterial Wall in Vivo: Implications of Radiofrequency Angioplasty” American Heart Journal vol. 117, pp. 332-341, 1982. |
| Codman & Shurtleff, Inc. “The Malis Bipolar Coagulating and Bipolar Cutting System CMC-II” brochure, early, 2 pgs, 1991. |
| Codman & Shurtleff, Inc. “The Malis Bipolar Electrosurgical System CMC-III Instruction Manual” , 15 pgs, Jul. 1991. |
| Cook et al., “Therapeutic Medical Devices: Application and Design” , Prentice Hall, Inc., 3pgs, 1982. |
| Dennis et al. “Evolution of Electrofulguration in Control of Bleeding of Experimental Gastric Ulcers,” Digestive Diseases and Sciences, vol. 24, No. 11, 845-848, Nov. 1979. |
| Dobbie, A.K., “The Electrical Aspects of Surgical Diathermy, Bio Medical Engineering” Bio-Medical Engineering vol. 4, pp. 206-216, May 1969. |
| Elsasser, V.E. et al., “An Instrument for Transurethral Resection without Leakage of Current” Acta Medicotechnica vol. 24, No. 4, pp. 129-134, 1976. |
| Geddes, “Medical Device Accidents: With Illustrative Cases” CRC Press, 3 pgs, 1998. |
| Honig, W., “The Mechanism of Cutting in Electrosurgery” IEEE pp. 58-65, 1975. |
| Kramolowsky et al. “The Urological App of Electorsurgery” J. of Urology vol. 146, pp. 669-674, 1991. |
| Kramolowsky et al. “Use of 5F Bipolar Electrosurgical Probe in Endoscopic Urological Procedures” J. of Urology vol. 143, pp. 275-277, 1990. |
| Lee, B et al. “Thermal Compression and Molding of Artherosclerotic Vascular Tissue with Use” JACC vol. 13(5), pp. 1167-1171, 1989. |
| Letter from Department of Health to Jerry Malis dated Jan. 24, 1991, 3 pgs. |
| Letter from Department of Health to Jerry Malis dated Jul. 25, 1985, 1 pg. |
| Letter from Jerry Malis to FDA dated Jul. 25, 1985, 2 pgs. |
| Lu, et al., “Electrical Thermal Angioplasty: Catheter Design Features, In Vitro Tissue Ablation Studies and In Vitro Experimental Findings,” Am J. Cardiol vol. 60, pp. 1117-1122, Nov. 1, 1987. |
| Malis, L., “Electrosurgery, Technical Note,” J. Neursurg., vol. 85, pp. 970-975, Nov. 1996. |
| Malis, L., “Excerpted from a seminar by Leonard I. Malis, M.D. at the 1995 American Association of Neurological Surgeons Meeting,” 1pg, 1995. |
| Malis, L., “Instrumentation for Microvascular Neurosurgery” Cerebrovascular Surgery, vol. 1, pp. 245-260, 1985. |
| Malis, L., “New Trends in Microsurgery and Applied Technology,” Advanced Technology in Neurosurgery, pp. 1-16, 1988. |
| Malis, L., “The Value of Irrigation During Bipolar Coagulation” See ARTC 21602, 1 pg, Apr. 9, 1993. |
| Nardella, P.C., SPIE 1068: pp. 42-49, Radio Frequency Energy and Impedance Feedback, 1989. |
| O'Malley, Schaum's Outline of Theory and Problems of Basic Circuit Analysis, McGraw-Hill, 2nd Ed., pp. 3-5, 1992. |
| Olsen MD, Bipolar Laparoscopic Cholecstectomy Lecture (marked confidential), 12 pgs, Oct. 7, 1991. |
| Pearce, John A. “Electrosurgery”, pp. 17, 69-75, 87, John Wiley & Sons, New York, 1986. |
| Pearce, John A., “Electrosurgery”, Handbook of Biomedical Engineering, chapter 3, Academic Press Inc., N.Y., pp. 98-113, 1988. |
| Piercey et al., “Electrosurgical Treatment of Experimental Bleeding Canine Gastric Ulcers” Gastroenterology vol. 74(3), pp. 527-534, 1978. |
| Protell et al., “Computer-Assisted Electrocoagulation: Bipolar v. Monopolar in the Treatment of Experimental Canine Gastric Ulcer Bleeding,” Gastroenterology vol. 80, No. 3, pp. 451-455, 1981. |
| Ramsey et al., “A Comparison of Bipolar and Monopolar Diathermy Probes in Experimental Animals”, Urological Research vol. 13, pp. 99-102, 1985. |
| Selikowitz et al., “Electric Current and Voltage Recordings on the Myocardium During Electrosurgical Procedures in Canines,” Surgery, Gynecology & Obstetrics, vol. 164 pp. 219-224, Mar. 1987. |
| Shuman, “Bipolar Versus Monopolar Electrosurgery: Clinical Applications,” Dentistry Today, vol. 20, No. 12, 7 pgs, Dec. 2001. |
| Slager et al. “Spark Erosion of Arteriosclerotic Plaques” Z. Kardiol. 76:Suppl. 6, pp. 67-71, 1987. |
| Slager et al. “Vaporization of Atherosclerotice Plaques by Spark Erosion” JACC 5(6): pp. 1382-1386, Jun. 1985. |
| Stoffels, E. et al., “Investigation on the Interaction Plasma-Bone Tissue”, E-MRS Spring Meeting, 1 pg, Jun. 18-21, 2002. |
| Stoffels, E. et al., “Biomedical Applications of Plasmas”, Tutorial presented prior to the 55th Gaseous Electronics Conference in Minneapolis, MN, 41 pgs, Oct. 14, 2002. |
| Stoffels, E. et al., “Plasma Interactions with Living Cells”, Eindhoven University of Technology, 1 pg, 2002. |
| Stoffels, E. et al., “Superficial Treatment of Mammalian Cells using Plasma Needle”, J. Phys. D: Appl. Phys. 26, pp. 2908-2913, Nov. 19, 2003. |
| Stoffels, E. et al., “Plasma Needle”, Eindhoven University of Technology, 1 pg, Nov. 28, 2003. |
| Stoffels, E. et al., “Plasma Physicists Move into Medicine”, Physicsweb, 1 pg, Nov. 2003. |
| Stoffels, E. et al., “Plasma Treated Tissue Engineered Skin to Study Skin Damage”, Biomechanics and Tissue Engineering, Materials Technology, 1 pg, 2003. |
| Stoffels, E. et al., “Plasma Treatment of Dental Cavities: A Feasibility Study”, IEEE Transaction on Plasma Science, vol. 32, No. 4, pp. 1540-1542, Aug. 2004. |
| Stoffels, E. et al., “The Effects of UV Irradiation and Gas Plasma Treatment on Living Mammalian Cells and Bacteria: A Comparative Approach”, IEEE Transaction on Plasma Science, vol. 32, No. 4, pp. 1544-1550, Aug. 2004. |
| Stoffels, E. et al., “Electrical and Optical Characterization of the Plasma Needle”, New Journal of Physics 6, pp. 1-14, Oct. 28, 2004. |
| Stoffels, E. et al., “Where Plasma Meets Plasma”, Eindhoven University of Technology, 23 pgs, 2004. |
| Stoffels, E. et al., “Gas Plasma effects on Living Cells”, Physica Scripta, T107, pp. 79-82, 2004. |
| Stoffels, E. et al., “Plasma Treatment of Mammalian Vascular Cells: A Quantitative Description”, IEEE Transaction on Plasma Science, vol. 33, No. 2, pp. 771-775, Apr. 2005. |
| Stoffels, E. et al., “Deactivation of Escherichia coli by the Plasma Needle”, J. Phys. D: Appl. Phys. 38, pp. 1716-1721, May 20, 2005. |
| Stoffels, E. et al., “Development of a Gas Plasma Catheter for Gas Plasma Surgery”, XXVIIth ICPIG, Endoven University of Technology, pp. 18-22, Jul. 2005. |
| Stoffels, E. et al., “Development of a Smart Positioning Sensor for the Plasma Needle”, Plasma Sources Sci. Technol. 15, pp. 582-589, Jun. 27, 2006. |
| Stoffels, E. et al., Killing of S. mutans Bacteria Using a Plasma Needle at Atmospheric Pressure, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1317-1324, Aug. 2006. |
| Stoffels, E. et al., “Plasma-Needle Treatment of Substrates with Respect to Wettability and Growth of Excherichia coli and Streptococcus mutans”, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1325-1330, Aug. 2006. |
| Stoffels, E. et al., “Reattachment and Apoptosis after Plasma-Needle Treatment of Cultured Cells”, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1331-1336, Aug. 2006. |
| Stoffels, E. et al., “UV Excimer Lamp Irradiation of Fibroblasts: The Influence on Antioxidant Homostasis”, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1359-1364, Aug. 2006. |
| Stoffels, E. et al., “Plasma Needle for In Vivo Medical Treatment: Recent Developments and Perspectives”, Plasma Sources Sci. Technol. 15, pp. S169-S180, Oct. 6, 2006. |
| Swain, C.P., et al., “Which Electrode, A Comparison of four endoscopic methods of electrocoagulation in experimental bleeding ulcers” Gut vol. 25, pp. 1424-1 431, 1987. |
| Tucker, R. et al. “A Comparison of Urologic Application of Bipolar Versus Monopolar Five French Electrosurgical Probes” J. of Urology vol. 141, pp. 662-665, 1989. |
| Tucker, R. et al. “In vivo effect of 5 French Bipolar and Monopolar Electrosurgical Probes on the Porcine Bladder ” Urological Research vol. 18, pp. 291-294, 1990. |
| Tucker, R. et al., “Demodulated Low Frequency Currents from Electrosurgical Procedures,” Surgery, Gynecology and Obstetrics, 159:39-43, 1984. |
| Tucker, R. et al., Abstract P14-11, p. 248, “A Bipolar Electrosurgical Turp Loop”, Nov. 1989. |
| Valley Forge Scientific Corp., “Summary of Safety and Effective Information from 510K”, 2pgs, 1991. |
| Valley Forge's New Products, CLINICA, 475, 5, Nov. 6, 1991. |
| Valleylab SSE2L Instruction Manual, 11 pgs, Jan. 6, 1983. |
| Valleylab, Inc. “Valleylab Part No. 945 100 102 A” Surgistat Service Manual, pgs. 1-46, Jul. 1988. |
| Wattiez, Arnaud et al., “Electrosurgery in Operative Endoscopy,” Electrosurgical Effects, Blackwell Science, pp. 85-93, 1995. |
| Wyeth, “Electrosurgical Unit” pp. 1181-1202, 2000. |
| BiLAP IFU 910033-002 Rev A for BiLAP Model 3527, L-Hook; BiLAP Model 3525, J-Hook; BiLAP Model 3529, High Angle, 2 pgs, Nov. 30, 1993. |
| BiLAP IFU 910026-001 Rev A for BiLAP Model 3525, J-Hook, 4 pgs, May 20, 1991. |
| BiLAP Generator Settings, Jun. 1991. |
| Tucker et al. “The interaction between electrosurgical generators, endroscopic electrodes, and tissue,” Gastrointestinal Endoscopy, vol. 38, No. 2, pp. 118-122, 1992. |
| “The 4th International Workshop on Microplasmas”, Conference Center of NCKU Library, 19 pgs, Oct. 28-31, 2007. |
| Amiel et al., “Bipolar Radiofrequency-based Microtenotomy: Basic Science, Clinical Outcomes and mechanism of Action”, Univ. of California, San Diego-Dept. of Orthopaedic Surg., San Diego Sports Med. and Orthopaedic Ctr, pp. 1-11, Mar. 29, 2007. |
| Balasubramanian et al., “Mechanism of Blood Coagulation by Non-Therman Atmospheric Pressure Dielectric Barrier Discharge Plasma”, IEEE Transactions on Plasma Science, vol. 35, Issue 5, Part 2, pp. 1559-1566, Oct. 2007. |
| Callaghan, Matthew J. et al., “Pulsed Electromagnetic Fields Accelerate Normal and Diabetic Wound Healing by Increasing Endogenous FGF-2 Release”, Plastic and Reconstructive Surgery Journal, vol. 121, No. 1, Diabetic Wound Healing, <www.PRSJournal.com>, pp. 130-141, Jan. 2007. |
| Fridman et al., “Applied Plasma Medicine”, Plasma Process. Polym., Drexel Univ., pp. 1-56, 2007. |
| Fridman et al., “Bio-Medical Applications of Non-Thermal Atmospheric Pressure Plasma”, 37th AIAA Plasmadynamics and Lasers Conference, 5 pgs, Jun. 5-8, 2006. |
| Fridman et al., “Blood Coagulation and Living Tissue Sterilization by Floating-electrode Dielectric Barrier Discharge in Air”, Plasma Chem Plasma Process, Springer Science+Business Media, Inc., 18pgs, Feb. 2006. |
| Fridman et al., “Comparison of Direct and Indirect Effects of Non-Thermal Atmospheric-Pressure Plasma on Bacteria”, Plasma Processes and Polymers, pp. 370-375, 2007. |
| Fridman et al., “Comparison of Sterilization by Floating Electrode Dielectric Barrier Discharge with Plasma Jet and Mechanisms of Observed Differences”, Drexel University Ninth Annual Research Innovation Scholarship and Creativity (RISC) Day, Drexel University, 1 pg, Apr. 17, 2007. |
| Fridman et al., “Floating Electrode Dielectric Barrier Discharge Plasma in Air Promoting Apoptotic Behavior in Melanoma Skin Cancer Cell Lines”, Plasma Chem Plasma Process, Springer Science+Business Media, LLC, 14 pgs, Jan. 2007. |
| Fridman et al., “Use of Non-Thermal Atmospheric Pressure Plasma Discharge for Coagulation and Sterilization of Surface Wounds”, 17th International Symposium on Plasma Chemistry (ISPC-17), Toronto, Canada, 6 pgs, Aug. 7-12, 2005. |
| Funk et al., “Effects of Electromagnetic Fields on Cells: Physiological and Therapeutical Approaches and Molecular Mechanisms of Interaction”, Cells Tissues Organs, vol. 182, pp. 59-78, 2006. |
| Hasan et al., “Sterilization using Atmospheric Pressure Non-Thermal Plasma”, STAR Scholars Program, Pennoni Honors College, Drexel University, 1 pg, Aug. 15, 2007. |
| Kalghatgi et al., “Mechanism of Blood Coagulation by Nonthermal Atmospheric Pressure Dielectric Barrier Discharge Plasma”, IEEE Transactions on Plasma Science, vol. 35, No. 5, pp. 1559-1566, Oct. 2007. |
| Lin et al., “Use of bipolar radiofrequency energy in delayed repair of acute supraspinatus tear in rats”, J. Shoulder Elbow Surg, pp. 1-9, 2007. |
| Marine et al., “Wound Sterilization and Promoted Healing using Non-thermal Atmospheric Pressure Plasma”, STAR Scholars Program, Pennoni Honors College, Drexel University, 1 pg, Apr. 2007. |
| O'Neill, Conor W. et al., “Percutaneous plasma decompression alters cytokine expression in injured porcine intervertebral discs”, The Spine Journal 4, pp. 88-98, 2004. |
| Ochiai et al., “Nerve Regeneration After Radiofrequency Application”, Am. J. Sports Med., pp. 1-5, 2007. |
| Rhyu, Kee-Won et al., “The short-term effects of electrosurgical ablation on proinflammatory mediator production by intervertebral disc cells in tissue culture”, The Spine Journal 7, pp. 451-458, 2007. |
| Robinson et al., “Biological and Medical Applications of Non-Thermal Atmospheric Pressure Plasma”, STAR Scholars Program, Pennoni Honors College, Drexel University, 1 pg, Aug. 15, 2007. |
| Silver et al., “Thermal Microdebridement Does not Affect the Time Zero Biomechanical Properties of Human Patellar Tendons”, Am. J. Sports Med., vol. 32, No. 8, pp. 1946-1952, 2004. |
| Takahashi et al., “Pain Relief Through and Antinociceptive Effect After Radiofrequency Application”, Am. J. Sports Med., vol. 35, No. 5, pp. 805-810, 2007. |
| Tasto et al., “Microtenotomy Using a Radiofrequency Probe to Treat Lateral Epicondylitis”, The Journal of Arthroscopic and Related Surgery, vol. 21, No. 7, pp. 851-860, Jul. 2005. |
| Tasto et al., “Radiofrequency Microtenotomy for Epicondylitis: Five-Year Follow-Up and Proposed Mechanism of Action (SS-65)”, Presented at Spring AANA 2008, 1pg, 2008. |
| Tasto et al., “Radiofrequency-based Microtenotomy for Chronic Tendinosis of the Foot and Ankle”, San Diego Sports Med. and Orthopaedic Ctr, Univ. of California San Diego—Dept. of Orthopaedics and Dept. of Biochem Research, Presented at the 2nd Triennial Scientific Meeting of the Int'l Federation of Foot and Ankle Societies, 1 pg, Sep. 2005. |
| Tasto et al., “Radiofrequency-Based Micro-Tenotomy for Treating Chronic Tendinosis”, San Diego Sports Med. and Orthopaedic Ctr, Univ. of California San Diego—Dept. of Orthopaedics, pp. 1-8, 2003. |
| Tasto, “The Use of Bipolar Radiofrequency Microtenotomy in the Treatment of Chronic Tendinosis of the Foot and Ankle”, Techniques in Foot and Ankle Surgery, vol. 5, Issue 2, pp. 110-116, 2006. |
| Taverna et al., “Arthroscopic Subacromial Decompression versus Radiofrequency (RF) Treatment for Rotator Cuff Tendinopathy A Study of Refractive Supraspinatus Tendinosis”, Istituto Ortopedico Galeazzi, Univ. of Milan (Italy), and Dept. of Orthopedics, Univ. of California San Diego, 2pgs, 2005. |
| Taverna et al., “Radiofrequency-Based Plasma Microtenotomy Compared with Arthroscopic Subacromial Decompression Yields Equivalent Outcomes for Rotator Cuff Tendinosis”, The Journal of Arthroscopic and Related Surgery, vol. 23, No. 10, pp. 1042-1051, Oct. 2007. |
| Weil, Jr. et al., “A New Minimally Invasive Technique for Treating Plantar Fasciosis Using Bipolar Radiofrequency: A Prospective Analysis”, Foot & Ankle Specialist, vol. 1, No. 1, pp. 13-18, Feb. 2008. |
| Weil, Sr. et al., “The Use of Percutaneous Topaz® Coblation for Plantar Fasciosis and Achilles Tendinosis”, Weil Foot & Ankle Institute, 1 pg, 2007. |
| Werber et al., “Plasma-Mediated Radiofrequency-Based Microtenotomy for Chronic Tendon Pathology in the Foot”, Presented at ACFAS in Las Vegas, NV, 1 pg, Mar. 2006. |
| Wrotslavsky et al., “A Novel Application of Bipolar Radiofrequency in Small Ankle Joints for Arthroscopic Synovectomy”, N. General Hospital/N.Y. College of Podiatric Med., New York, Presented as a poster at the ACFAS annual meeting in Las Vegas, NV, 1 pg, Mar. 20-21, 2006. |
| Zang, “Plantar Fasciosis Syndrome: A Retrospective Report on the Endoscopic Micro-Fasciotomy Technique, a Fascia Preservation Procedure”, Presented as a poster at the ACFAS annual meeting in Las Vegas, NV, 1 pg, Mar. 20-21, 2006. |
| Zang, “Plantar Plate Derangement with Synovitis of the Second Metatarsal Phalangeal Joint Complex: An Alternative Less Invasive Approach to Surgical Dissection”, Presented as a poster at the ACFAS annual meeting in Las Vegas, NV, 1pg, Mar. 20-21, 2006. |
| Buchelt, et al. “Excimer Laser Ablation of Fibrocartilage: An In Vitro and In Vivo Study”, Lasers in Surgery and Medicine, vol. 11, pp. 271-279, 1991. |
| Costello et al., “Nd: YAG Laser Ablation of the Prostate as a Treatment for Benign Prostatic Hypertrophy”, Lasers in Surgery and Medicine, vol. 12, pp. 121-124, 1992. |
| Rand et al., “Effect of Elecctrocautery on Fresh Human Articular Cartilage”, J. Arthro. Surg., vol. 1, pp. 242-246, 1985. |
| O'Neill et al., “Percutaneous Plasma Discectomy Stimulates Repair in Injured Porcine Intervertebral Discs”, Dept. of Orthopaedic Surgery, Dept. of Radiology University of California at San Francisco, CA, 3 pgs. |
| PCT International Search Report for PCT/US99/14685, 1 pg, Mailed Oct. 21, 1999. |
| PCT Notification of International Preliminary Examination Report for PCT/US99/14685, 4 pgs, Mailed Feb. 20, 2001. |
| PCT International Search Report for PCT/US98/22323, 1 pg, Mailed Mar. 3, 1999. |
| PCT Notification of International Preliminary Examination Report for PCT/US98/22323, 5 pgs, Mailed Nov. 28, 2000. |
| European Search Report for EP 98953859, 2 pgs, Jul. 2, 2001. |
| Supplementary European Search Report for EP 98953859, 3 pgs, Oct. 18, 2001. |
| PCT International Search Report for PCT/US99/18289, 1 pg, Mailed Dec. 7, 1999. |
| PCT Notification of International Preliminary Examination Report for PCT/US99/18289, 4 pgs, Mailed Jul. 7, 2000. |
| European Search Report for EP 99945039.8, 3 pgs, Oct. 1, 2001. |
| PCT International Search Report for PCT/US02/19261, 1 pg, Mailed Sep. 18, 2002. |
| PCT International Preliminary Examination Report for PCT/US02/19261, 3 pgs, Mar. 25, 2003. |
| PCT International Search Report for PCT/US02/29476, 1 pg, Mailed May 24, 2004. |
| PCT International Search Report for PCT/US03/13686, 1 pg, Mailed Nov. 25, 2003. |
| PCT International Search Report for PCT/US04/03614, 1 pg, Mailed Sep. 14, 2004. |
| PCT Written Opinion of the International Searching Authority for PCT/US04/03614, 4 pgs, Mailed Sep. 14, 2004. |
| PCT Notification of International Search Report and Written Opinion for PCT/US06/26321, 8pgs, Mailed Apr. 25, 2007. |
| PCT Notification of the International Search Report and Written Opinion for PCT/US06/60618, 7pgs, Mailed Oct. 5, 2007. |
| PCT Notification of the International Search Report and Written Opinion for PCT/US07/69856, 7pgs, Mailed Jun. 5, 2008. |
| UK Search Report for GB0805062.7 1 pg, Jul. 16, 2008. |
| European Search Report for EP 02773432 3pgs, Dec. 19, 2008. |
| European Examination Report for EP 05024974 4 pgs, Dec. 5, 2008. |
| UK Search Report for GB0800129.9 2pgs, May 8, 2008. |
| Non-Final Office Action for U.S. Appl. No. 11/327,089, 12 pgs, Mailed Oct. 7, 2008. |
| Notice of Allowance and Fees Due for U.S. Appl. No. 11/327,089 15 pgs, Mailed May 8, 2009. |
| European Examination Report (3rd) for EP 04708664 6pgs, Nov. 6, 2012. |
| Number | Date | Country | |
|---|---|---|---|
| 20090209958 A1 | Aug 2009 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11327089 | Jan 2006 | US |
| Child | 12430181 | US |
